Document is current
Any future updates will be listed below
-
Authors
Neary, Maureen P.
Catillon, Maryaline
Ahmad, Nina
Gauthier-Loiselle, Marjolaine
Geurtsen, Jeroen
Qu, Alice
Willame, Corinne
Cloutier, Martin
El Khoury, Antoine C.
Saade, Elie
-
Funding
Funding for this research was provided by:
Janssen Global Services, LLC.
- License Information
-
More Information
Article History
Received: 3 September 2024
Accepted: 9 December 2024
First Online: 7 February 2025
Declarations
:
: Antoine C. El Khoury and Nina Ahmad are employees of Janssen Global Services, LLC. Maureen P. Neary is currently an employee of Sanofi, but was an employee of Janssen Global Services, LLC at the time of manuscript development. Corinne Willame is an employee of Janssen Pharmaceutica NV. Jeroen Geurtsen is an employee of Janssen Vaccines & Prevention BV. Maryaline Catillon, Marjolaine Gauthier-Loiselle, Martin Cloutier, and Alice Qu are employees of Analysis Group, Inc., which has received consultancy fees from Janssen Global Services, LLC for the conduct of this study. Elie Saade reports research grants from Janssen; research grants and speaking and lecture fees and travel reimbursement from Sanofi Pasteur; advisory board relationship and research grants from Pfizer; and research grants from Seqirus.
: This claims-based study was considered exempt from review by an institutional review board under 45 CFR § 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR § 164.514.
